While these events increased the Company’s outstanding share count, they also reduced outstanding debt on a dollar-for-dollar basis and strengthened the Company’s balance sheet. The underlying value ...

Following a year of operational reevaluation and bold decision-making, ProPhase has emerged with a significantly leaner structure, stronger balance sheet, and a renewed commitment to its core growth ...

A COMPLEX, linear structure along the axis of certain meiotic prophase chromosomes has been observed in several animal spermatocytes 1–5. Such structure has never been detected in mitosis or other ...

UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today ...

Access the complete ProPhase Labs Research Report, along with 1,400+ other detailed company analyses, exclusively on InvestingPro. In other recent news, ProPhase Labs Inc. has reported its ...

Medical diagnostic and testing concern ProPhase Labs, Inc. gets put in the spotlight today. ProPhase Labs, Inc. has seen huge revenue growth from Covid testing but is rapidly diversifying into other ...

The latest price target for ProPhase Labs (NASDAQ:PRPH) was reported by HC Wainwright & Co. on February 21, 2024. The analyst firm set a price target for $11.00 expecting PRPH to rise to within 12 ...

ProPhase Labs is a diversified biotech company with profitable existing product lines and plans for expansion. The company's subsidiary, Nebula Genomics, offers whole genome sequencing and plans to ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

ProPhase Labs, Inc. announced that CEO Ted Karkus will present at the upcoming Investor Summit Virtual on March 11, 2025, at 1:30 P.M. ET, offering investors insights into the company's operations and ...